Skip to main
  1. Stocks
  2. Journey Medical Corp
  3. Forecast
DERM

DERM Stock Forecast & Price Target

DERM Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Journey Medical is supported by a commercial ramp in Emrosi that is already demonstrating strong underlying demand, with 3Q26 revenue of $19.0M, Emrosi sales of $9.0M, and prescriptions up 98.6% year over year while unique prescribers topped 5,000 and refill rates rose about 12% quarter over quarter. The bullish case is strengthened by improving access, including the largest U.S. national health plan covering 25M+ lives beginning in January 2027, which should lift quality coverage and convert signed formulary wins into reimbursed volume. Financially, gross margin expanded to 69%, adjusted EBITDA reached $3.5M, and EBITDA was positive for a second straight quarter, showing the business can scale profitably as coverage broadens.

Bears say

Journey Medical is facing a weak fundamental setup because its key dermatology products appear vulnerable to slower-than-expected adoption, competitive branded generics, and payer pressure, with 3Q26 prescriptions already declining 0.7% sequentially for Qbrexza and 12.9% for Accutane. The company’s outlook is further pressured by regulatory and patent uncertainty, since pipeline success does not ensure FDA approval and an unfavorable Qbrexza litigation outcome could allow Perrigo to launch a generic earlier than projected. Financially, lower revenue expectations have already led to 2026 EPS being cut to $(0.29) from $(0.06) and 2027 EPS to $0.15 from $1.07, while the need for additional capital could also dilute shareholders.

DERM has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Journey Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

DERM Analyst Forecast & Price Prediction

Get the latest DERM stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DERM

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Journey Medical Corp (DERM) Forecast

Analysts have given DERM a Strong Buy based on their latest research and market trends.

According to 2 analysts, DERM has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Journey Medical Corp (DERM)


DERM Analyst Forecast & Price Prediction

Get the latest DERM stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in DERM

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover DERM stock data and trends